Share on StockTwits

ImmunoCellular Therapeutics (NASDAQ:IMUC) VP Anthony Gringeri acquired 11,000 shares of the stock on the open market in a transaction dated Thursday, August 21st. The shares were purchased at an average price of $0.91 per share, with a total value of $10,010.00. The purchase was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $3.31.

ImmunoCellular Therapeutics (NASDAQ:IMUC) traded up 1.44% during mid-day trading on Friday, hitting $0.913. 256,740 shares of the company’s stock traded hands. ImmunoCellular Therapeutics has a 52-week low of $0.65 and a 52-week high of $4.00. The stock has a 50-day moving average of $0.97 and a 200-day moving average of $1.16. The company’s market cap is $55.4 million.

ImmunoCellular Therapeutics (NASDAQ:IMUC) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, analysts predict that ImmunoCellular Therapeutics will post $-0.22 EPS for the current fiscal year.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.